Exagen Retained Earnings vs Cash And Short Term Investments Analysis
XGN Stock | USD 1.95 0.03 1.56% |
Exagen financial indicator trend analysis is much more than just examining Exagen Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Exagen Inc is a good investment. Please check the relationship between Exagen Retained Earnings and its Cash And Short Term Investments accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Retained Earnings vs Cash And Short Term Investments
Retained Earnings vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Exagen Inc Retained Earnings account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Exagen's Retained Earnings and Cash And Short Term Investments is -0.67. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Exagen Inc, assuming nothing else is changed. The correlation between historical values of Exagen's Retained Earnings and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Exagen Inc are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Retained Earnings i.e., Exagen's Retained Earnings and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | -0.67 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Exagen Inc balance sheet. This account contains Exagen investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Exagen Inc fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Exagen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Exagen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. At this time, Exagen's Tax Provision is very stable compared to the past year. As of the 1st of June 2024, Enterprise Value is likely to grow to about 27.9 M, while Selling General Administrative is likely to drop about 30.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 2.6M | 2.4M | 2.3M | 2.8M | Depreciation And Amortization | 16K | 830K | 2.2M | 2.3M |
Exagen fundamental ratios Correlations
Click cells to compare fundamentals
Exagen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Exagen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 88.3M | 78.4M | 123.4M | 86.2M | 56.9M | 54.2M | |
Short Long Term Debt Total | 25.9M | 26.7M | 27.5M | 34.5M | 23.7M | 23.8M | |
Other Current Liab | 4.2M | 5.4M | 6.2M | 5.3M | 7.0M | 4.0M | |
Total Current Liabilities | 5.9M | 8.8M | 9.3M | 9.6M | 11.9M | 9.7M | |
Total Stockholder Equity | 55.7M | 41.8M | 84.9M | 42.5M | 22.7M | 20.5M | |
Property Plant And Equipment Net | 1.4M | 2.1M | 4.8M | 13.1M | 8.5M | 8.9M | |
Net Debt | (46.2M) | (30.8M) | (72.0M) | (27.9M) | (12.8M) | (13.4M) | |
Retained Earnings | (164.6M) | (181.3M) | (208.1M) | (255.5M) | (279.2M) | (265.3M) | |
Accounts Payable | 1.5M | 3.0M | 2.5M | 3.0M | 3.1M | 2.1M | |
Cash | 72.1M | 57.4M | 99.4M | 62.4M | 36.5M | 37.0M | |
Non Current Assets Total | 7.1M | 7.9M | 10.7M | 13.6M | 9.1M | 10.2M | |
Non Currrent Assets Other | 503K | 174K | (487K) | (391K) | 528K | 416K | |
Cash And Short Term Investments | 72.1M | 57.4M | 99.4M | 62.4M | 36.5M | 37.0M | |
Common Stock Shares Outstanding | 12.6M | 12.7M | 16.0M | 17.1M | 17.7M | 18.6M | |
Liabilities And Stockholders Equity | 88.3M | 78.4M | 123.4M | 86.2M | 56.9M | 54.2M | |
Non Current Liabilities Total | 26.8M | 27.8M | 29.2M | 34.1M | 22.3M | 20.3M | |
Other Current Assets | 3.5M | 4.2M | 3.6M | 4.1M | 1.9M | 2.1M | |
Other Stockholder Equity | 220.2M | 223.1M | 293.1M | 298.0M | 301.9M | 164.6M | |
Total Liab | 32.7M | 36.5M | 38.5M | 43.8M | 34.3M | 33.7M | |
Property Plant And Equipment Gross | 1.4M | 2.1M | 4.8M | 13.1M | 14.3M | 15.0M | |
Total Current Assets | 81.3M | 70.5M | 112.7M | 72.6M | 47.8M | 44.0M | |
Short Term Debt | 238K | 308K | 587K | 1.2M | 1.7M | 1.6M | |
Other Assets | 174K | 250K | 433K | 528K | 475.2K | 894.3K | |
Net Receivables | 5.7M | 8.9M | 9.7M | 6.1M | 6.6M | 6.0M | |
Property Plant Equipment | 1.4M | 2.1M | 4.8M | 13.1M | 15.0M | 15.8M | |
Other Liab | 266K | 530K | 1.7M | 19K | 17.1K | 16.2K | |
Net Tangible Assets | 50.2M | 36.3M | 79.4M | 42.5M | 48.8M | 51.3M | |
Long Term Debt | 25.9M | 26.7M | 27.5M | 28.8M | 19.2M | 21.0M | |
Capital Lease Obligations | 238K | 308K | 587K | 6.2M | 4.2M | 4.4M | |
Inventory | 1.4M | 1.2M | 1.1M | 1.8M | 2.9M | 3.0M | |
Non Current Liabilities Other | 638K | 948K | 1.4M | 867K | 357K | 567.1K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Exagen Inc information on this page should be used as a complementary analysis to other Exagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Exagen Stock analysis
When running Exagen's price analysis, check to measure Exagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exagen is operating at the current time. Most of Exagen's value examination focuses on studying past and present price action to predict the probability of Exagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exagen's price. Additionally, you may evaluate how the addition of Exagen to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Exagen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 3.134 | Quarterly Revenue Growth 0.284 | Return On Assets (0.17) | Return On Equity (0.69) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.